title: Re: Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2014;16(2):278-88.
authors: Florida A&M University (FAMU) , Tallahassee, FL , USA.
authors: Vakaramoko
authors: V
authors: Diaby
authors: Georges
authors: G
authors: Adunlin
authors: Alberto J
authors: AJ
authors: Montero
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002017:Budgets; D016527:Drug Costs / Q000639:trends*; D066246:ErbB Receptors; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases; D020123:Sirolimus / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D020123:Sirolimus